These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 38761776)

  • 1. Senolytic combination of dasatinib and quercetin attenuates renal damage in diabetic kidney disease.
    Guo X; Wen S; Wang J; Zeng X; Yu H; Chen Y; Zhu X; Xu L
    Phytomedicine; 2024 Jul; 130():155705. PubMed ID: 38761776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Senolytic combination of dasatinib and quercetin protects against diabetic kidney disease by activating autophagy to alleviate podocyte dedifferentiation via the Notch pathway.
    Zhu X; Zhang C; Liu L; Xu L; Yao L
    Int J Mol Med; 2024 Mar; 53(3):. PubMed ID: 38240118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PPARα/δ dual agonist H11 alleviates diabetic kidney injury by improving the metabolic disorders of tubular epithelial cells.
    Ke Q; Xiao Y; Liu D; Shi C; Shen R; Qin S; Jiang L; Yang J; Zhou Y
    Biochem Pharmacol; 2024 Apr; 222():116076. PubMed ID: 38387308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epiberberine ameliorated diabetic nephropathy by inactivating the angiotensinogen (Agt) to repress TGFβ/Smad2 pathway.
    Xiao Y; Deng J; Li C; Gong X; Gui Z; Huang J; Zhang Y; Liu Y; Ye X; Li X
    Phytomedicine; 2021 Mar; 83():153488. PubMed ID: 33571918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteomic and lipidomic analysis of the mechanism underlying astragaloside IV in mitigating ferroptosis through hypoxia-inducible factor 1α/heme oxygenase 1 pathway in renal tubular epithelial cells in diabetic kidney disease.
    Liu J; Ren J; Zhou L; Tan K; Du D; Xu L; Cao W; Zhang Y
    J Ethnopharmacol; 2024 Nov; 334():118517. PubMed ID: 38972525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chlorogenic acid alleviates renal fibrosis by reducing lipid accumulation in diabetic kidney disease through suppressing the Notch1 and Stat3 signaling pathway.
    Yang XY; Jiang D; Wang YZ; Duan MY; Huang YW; Wang XJ; Xiang ZM; Sheng J; Zhu QQ
    Ren Fail; 2024 Dec; 46(2):2371988. PubMed ID: 38952291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baicalin ameliorates renal fibrosis by upregulating CPT1α-mediated fatty acid oxidation in diabetic kidney disease.
    Hu H; Li W; Hao Y; Peng Z; Zou Z; Liang W
    Phytomedicine; 2024 Jan; 122():155162. PubMed ID: 37922789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alpha lipoamide inhibits diabetic kidney fibrosis via improving mitochondrial function and regulating RXRα expression and activation.
    Zhang HF; Liu HM; Xiang JY; Zhou XC; Wang D; Chen RY; Tan WL; Liang LQ; Liu LL; Shi MJ; Zhang F; Xiao Y; Zhou YX; Zhang T; Tang L; Guo B; Wang YY
    Acta Pharmacol Sin; 2023 May; 44(5):1051-1065. PubMed ID: 36347997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nephroprotective effect of Combretum micranthum G. Don in nicotinamide-streptozotocin induced diabetic nephropathy in rats: In-vivo and in-silico experiments.
    Kpemissi M; Potârniche AV; Lawson-Evi P; Metowogo K; Melila M; Dramane P; Taulescu M; Chandramohan V; Suhas DS; Puneeth TA; S VK; Vlase L; Andrei S; Eklu-Gadegbeku K; Sevastre B; Veerapur VP
    J Ethnopharmacol; 2020 Oct; 261():113133. PubMed ID: 32673708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Canagliflozin improves fatty acid oxidation and ferroptosis of renal tubular epithelial cells via FOXA1-CPT1A axis in diabetic kidney disease.
    Gan T; Wang Q; Song Y; Shao M; Zhao Y; Guo F; Wei F; Fan X; Zhang W; Luo Y; Chen D; Wang S; Qin G
    Mol Cell Endocrinol; 2024 Mar; 582():112139. PubMed ID: 38128823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medications Activating Tubular Fatty Acid Oxidation Enhance the Protective Effects of Roux-en-Y Gastric Bypass Surgery in a Rat Model of Early Diabetic Kidney Disease.
    Martin WP; Chuah YHD; Abdelaal M; Pedersen A; Malmodin D; Abrahamsson S; Hutter M; Godson C; Brennan EP; Fändriks L; le Roux CW; Docherty NG
    Front Endocrinol (Lausanne); 2021; 12():757228. PubMed ID: 35222262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impairment of PPAR
    Chung KW; Lee EK; Lee MK; Oh GT; Yu BP; Chung HY
    J Am Soc Nephrol; 2018 Apr; 29(4):1223-1237. PubMed ID: 29440279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Astragaloside IV Alleviates Renal Tubular Epithelial-Mesenchymal Transition via CX3CL1-RAF/MEK/ERK Signaling Pathway in Diabetic Kidney Disease.
    Hu Y; Tang W; Liu W; Hu Z; Pan C
    Drug Des Devel Ther; 2022; 16():1605-1620. PubMed ID: 35669284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Micheliolide ameliorates diabetic kidney disease by inhibiting Mtdh-mediated renal inflammation in type 2 diabetic db/db mice.
    Liu W; Chen X; Wang Y; Chen Y; Chen S; Gong W; Chen T; Sun L; Zheng C; Yin B; Li S; Luo C; Huang Q; Xiao J; Xu Z; Peng F; Long H
    Pharmacol Res; 2019 Dec; 150():104506. PubMed ID: 31669149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease.
    Hickson LJ; Langhi Prata LGP; Bobart SA; Evans TK; Giorgadze N; Hashmi SK; Herrmann SM; Jensen MD; Jia Q; Jordan KL; Kellogg TA; Khosla S; Koerber DM; Lagnado AB; Lawson DK; LeBrasseur NK; Lerman LO; McDonald KM; McKenzie TJ; Passos JF; Pignolo RJ; Pirtskhalava T; Saadiq IM; Schaefer KK; Textor SC; Victorelli SG; Volkman TL; Xue A; Wentworth MA; Wissler Gerdes EO; Zhu Y; Tchkonia T; Kirkland JL
    EBioMedicine; 2019 Sep; 47():446-456. PubMed ID: 31542391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dietary restriction and medical therapy drives PPARα-regulated improvements in early diabetic kidney disease in male rats.
    Martin WP; Nair M; Chuah YHD; Malmodin D; Pedersen A; Abrahamsson S; Hutter M; Abdelaal M; Elliott JA; Fearon N; Eckhardt H; Godson C; Brennan EP; Fändriks L; le Roux CW; Docherty NG
    Clin Sci (Lond); 2022 Nov; 136(21):1485-1511. PubMed ID: 36259366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quercetin improves diabetic kidney disease by inhibiting ferroptosis and regulating the Nrf2 in streptozotocin-induced diabetic rats.
    Zhang L; Wang X; Chang L; Ren Y; Sui M; Fu Y; Zhang L; Hao L
    Ren Fail; 2024 Dec; 46(1):2327495. PubMed ID: 38465879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dapagliflozin attenuates AKI to CKD transition in diabetes by activating SIRT3/PGC1-α signaling and alleviating aberrant metabolic reprogramming.
    Li H; Xia Y; Zha H; Zhang Y; Shi L; Wang J; Huang H; Yue R; Hu B; Zhu J; Song Z
    Biochim Biophys Acta Mol Basis Dis; 2024 Oct; 1870(7):167433. PubMed ID: 39067538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trigonelline inhibits tubular epithelial-mesenchymal transformation in diabetic kidney disease via targeting Smad7.
    Gong M; Guo Y; Dong H; Wu W; Wu F; Lu F
    Biomed Pharmacother; 2023 Dec; 168():115747. PubMed ID: 37864898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Huangkui capsule, an extract from Abelmoschus manihot (L.) medic, improves diabetic nephropathy via activating peroxisome proliferator-activated receptor (PPAR)-α/γ and attenuating endoplasmic reticulum stress in rats.
    Ge J; Miao JJ; Sun XY; Yu JY
    J Ethnopharmacol; 2016 Aug; 189():238-49. PubMed ID: 27224243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.